On Demand 2025 Friday AM General Sessions

This course contains the following sessions from Friday's morning program:

  • Clinical Conundrums in Anaphylaxis: Let the Practice Parameters Be Your Guide
  • Insights into Eosinophilic Lung Diseases
  • WAO - World Allergy Forum – Management of Severe Immunoallergic Diseases: Where Are We Going?
  • Earth, Wind and Fire: Impacts of Climate Change and the Atopic Patient

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 6.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Recognize diagnostic characteristics of clinical patterns of anaphylactic reaction.
  • Assess the utility of serum tryptase measurements in anaphylaxis.
  • Assist patients in making preference-sensitive decisions regarding diagnosis and treatment of anaphylaxis.
  • Differentiate ABPA and airway mycosis from other airway disease and discuss contemporary targeted treatment options.
  • Identify the pathogenesis and clinical spectrum of non-asthmatic eosinophilic lung disease (including, but not limited to hypereosinophilic syndrome, chronic eosinophilic pneumonia, and interstitial lung disease) and assess best practices for evaluation and management of patients with these suspected diseases.
  • Examine the role of biologics and newer therapies in non-asthmatic eosinophilic lung disease.
  • Apply insights from a fellow allergist who weathered a major natural disaster.
  • Investigate how more frequent and intense storms have immediate effects on mold and pollen, worsening allergic respiratory diseases.
  • Explore how frequent wildfires worsen air quality, triggering asthma and COPD, and the impact of pollution and rising temperatures on ecosystems. Develop effective procedures to be used during natural disasters that impact a Practice.
  • Describe current concepts in the early suspicion and early treatment of patients with anaphylaxis.
  • Discuss the main reactions of food allergy, the keys to diagnosis, and advances in current treatment.
  • Explain the endotypes and phenotypes, as well as the most recent advances in biomarkers and treatment that lead to remission. Identify the main types of hereditary angioedema and the latest approaches to diagnosis and treatment.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Attendance
  • 6.00 CBRN
Course opens: 
11/24/2025
Course expires: 
12/07/2028
Part of: 
On Demand ACAAI 2025 Annual Scientific Meeting
Rating: 
0

Jay A. Lieberman, MD, FACAAI
David BK Golden, MD, FACAAI
Marcus S. Shaker, MD, FACAAI
Dennis K. Ledford, MD, FACAAI
Paneez Khoury, MD
Praveen Akuthota, MD
Motohiro Ebisawa, MD, PhD
Alessandro Fiocchi, MD
Giorgio W. Canonica, MD
Allen P. Kaplan, MD, FACAAI
Jeffrey G. Demain, MD, FACAAI
Bryan L. Martin, DO, FACAAI
Paul V. Williams, MD, FACAAI
Javed Sheikh, MD, FACAAI
 

Available Credit

  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Attendance
  • 6.00 CBRN
Please login or create an account to take this course.